Herantis Pharma

1.385

EUR

-1.07 %

HRTIS

First North Finland

Biotechnology & Pharmaceuticals

Health Care

4,234 following

-1.07%

-13.44%

-8.58%

+12.6%

-17.56%

-2.81%

-28.61%

-81.45%

-86.25%

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Market cap

33.37M EUR

Turnover

17.86K EUR

P/E (adj.) (24e)

-5.31

EV/EBIT (adj.) (24e)

-5.32

P/B (24e)

132.97

EV/S (24e)

2,796.3

Dividend yield-% (24e)

-

Coverage

Recommendation

Accumulate

Target price

2.20 EUR

Updated

23.08.2024

Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 23.08.2024

Latest extensive report

Released: 25.06.2024

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

6.3

2025

Annual report '24

24.4

2025

General meeting '25

21.8

2025

Interim report Q2'25

Risk

Business risk

Valuation risk

Low

High

ShowingAll content types

Herantis Pharma, Webcast, Q4'24

Webcast3/6/2025, 12:30 PM

Herantis Pharma, Webcast, Q4'24

Herantis Pharma

Regulatory press release2/18/2025, 2:00 PM

Herantis Pharma: Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act

Herantis Pharma

Regulatory press release2/17/2025, 7:20 AM

Herantis Pharma Plc: 1,311,363 new shares registered with the trade register

Herantis Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release2/10/2025, 6:35 AM

Herantis Pharma Plc: 2,622,721 new shares registered with the trade register

Herantis Pharma

Analyst Comment2/7/2025, 6:39 AM by

Herantis Pharma collected 5.2 MEUR in gross assets from the directed share issue as expected

The funds raised in the issue will strengthen the company's financial position until the topline data of the HER-096 phase 1b trial are released in Q3'25. The company commented that it will continue its partnership discussions and preparations for the phase 2 trial.

Herantis Pharma

Regulatory press release2/6/2025, 6:30 PM

Inside information: Herantis Pharma Plc successfully completes a directed share issue raising EUR 5.2 million

Herantis Pharma

Analyst Comment1/28/2025, 9:25 AM by

Herantis Pharma Phase 1b clinical trial is progressing

Herantis reported in a press release that the first patient with Parkinson's disease received a test dose of the drug in the second part of the Phase 1b clinical trial.

Herantis Pharma

Press release1/28/2025, 7:00 AM

Herantis Pharma: encouraging pharmacokinetic data and first subject with Parkinson’s disease dosed in the Phase 1b trial

Herantis Pharma

Regulatory press release1/20/2025, 11:15 AM

Herantis Pharma Oyj: Managers' Transactions – Aki Prihti

Herantis Pharma

Regulatory press release1/20/2025, 11:00 AM

Herantis Pharma Oyj: Managers' Transactions – Aki Prihti

Herantis Pharma

Drug development investment: Value creation through M&As and licensing agreements

Article12/19/2024, 11:07 AM by

Drug development investment: Value creation through M&As and licensing agreements

The fourth part of our series of articles focusing on investing in Life Science companies deals with value creation in drug development companies through M&As and licensing agreements.

Faron Pharmaceuticals Herantis Pharma Orion Modulight

Regulatory press release12/12/2024, 2:00 PM

Herantis Pharma’s financial calendar and annual general meeting for 2025

Herantis Pharma

Regulatory press release12/10/2024, 4:30 PM

Proposals of the Shareholders' Nomination Committee to Herantis Pharma Plc's Annual General Meeting 2025

Herantis Pharma

Herantis Pharma as an Investment | Life Science Night Dec. 2, 2024

Video12/3/2024, 12:50 PM

Herantis Pharma as an Investment | Life Science Night Dec. 2, 2024

Antti Vuolanto, CEO, talks about biotechnology company Herantis Pharma as an investment.

Herantis Pharma

Regulation of drug development

Analyst Comment12/3/2024, 10:21 AM by

Regulation of drug development

The third part in our series of articles on investing in Life Science companies deals with regulatory issues. Regulatory processes are demanding and time-consuming, and failure to comply can be disastrous for a drug development company.

Faron Pharmaceuticals Herantis Pharma Orion Mendus Modulight

Analyst Comment12/3/2024, 6:52 AM

Life Science Night available on inderesTV

Aiforia Technologies Herantis Pharma Faron Pharmaceuticals

Life Science Companies as Investments | Life Science Night Dec. 2, 2024

Video12/2/2024, 2:00 PM

Life Science Companies as Investments | Life Science Night Dec. 2, 2024

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia Technologies BBS-Bioactive Bone Substitutes Bioretec Biohit Faron Pharmaceuticals Modulight Nexstim Orion Bittium Detection Technology Optomed Revenio Group Nightingale Health Herantis Pharma Nanoform Finland

Life Science Night | December 2, 2024

Webcast12/2/2024, 2:00 PM

Life Science Night | December 2, 2024

Welcome to follow Life Science Night on Monday, December 2 at 4:00 pm EET on inderesTV.

Aiforia Technologies Herantis Pharma Faron Pharmaceuticals

Analyst Comment11/12/2024, 6:53 AM by

Part 1 of the Herantis trial completed

Herantis issued a press release on Monday announcing the completion of the Part 1 of the Phase Ib clinical trial of the drug candidate HER-096 in healthy volunteers.

Herantis Pharma

Press release11/11/2024, 3:05 PM

Herantis Pharma has successfully completed the Part 1 of the Phase 1b clinical trial

Herantis Pharma

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.